Details for Patent: RE43298
✉ Email this page to a colleague
Which drugs does patent RE43298 protect, and when does it expire?
Patent RE43298 protects VICTRELIS and is included in one NDA.
This patent has eighty-three patent family members in thirty-three countries.
Summary for Patent: RE43298
| Title: | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| Abstract: | The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. |
| Inventor(s): | Saksena; Anil K. (Upper Montclair, NJ), Girijavallabhan; Viyyoor Moopil (Parsippany, NJ), Lovey; Raymond G. (West Caldwell, NJ), Jao; Edwin (Warren, NJ), Bennett; Frank (Cranford, NJ), McCormick; Jinping L. (Edison, NJ), Wang; Haiyan (Cranbury, NJ), Pike; Russell E. (Stanhope, NJ), Bogen; Stephane L. (Somerset, NJ), Chan; Tin-Yau (Edison, NJ), Liu; Yi-Tsung (Morris Township, NJ), Zhu; Zhaoning (East Windsor, NJ), Njoroge; F. George (Warren, NJ), Arasappan; Ashok (Bridgewater, NJ), Parekh; Tejal (Mountain View, CA), Ganguly; Ashit K. (Upper Montclair, NJ), Chen; Kevin X. (Edison, NJ), Venkatraman; Srikanth (Fords, NJ), Vaccaro; Henry M. (South Plainfield, NJ), Pinto; Patrick A. (Morris Plains, NJ), Santhanam; Bama (Bridgewater, NJ), Kemp; Scott Jeffrey (San Diego, CA), Levy; Odile Esther (San Diego, CA), Lim-Wilby; Marguerita (Santa Fe, NM), Tamura; Susan Y. (Santa Fe, NM), Wu; Wanli (Edison, NJ), Hendrata; Siska (Edison, NJ), Huang; Yuhua (Scotch Plains, NJ) |
| Assignee: | Schering Corporation (Kenilworth, NJ) Dendreon Corporation (San Diego, CA) |
| Application Number: | 13/068,159 |
|
Patent Claim Types: see list of patent claims | Compound; Use; Composition; |
Drugs Protected by US Patent RE43298
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | VICTRELIS | boceprevir | CAPSULE;ORAL | 202258-001 | May 13, 2011 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent RE43298
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 033985 | ⤷ Try a Trial | |||
| Argentina | 038183 | ⤷ Try a Trial | |||
| Argentina | 069373 | ⤷ Try a Trial | |||
| Austria | 461207 | ⤷ Try a Trial | |||
| Austria | 469914 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
